Articles from Leyden Laboratories B.V.

Dutch biotech Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced a €40 million investment from the European Innovation Council (EIC) Fund, Invest-NL, Gates Foundation, ClavystBio, and others. The financing brings together a strong group of impact-focused investors from Europe, the United States, and Asia to support novel approaches that could better protect people worldwide against influenza and other respiratory viruses. Respiratory viruses are a global concern, requiring global access to reach the most vulnerable patients around the world, both in seasonal and pandemic situations.

Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced landmark preclinical and clinical data in Science Translational Medicine supporting the development of their antibody-based nasal sprays to prevent influenza infection by neutralizing virus at portal of entry.

Dutch biotech Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced €30 million in new equity financing from the European Innovation Council (EIC) Fund and Invest-NL to advance the Company’s clinical development of its pan-influenza nasal spray (PanFlu) and broader mucosal pipeline and platform activities.

The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden Laboratories B.V. have signed a €20 million financing deal to advance development of the Company’s broadly-protective antibodies to defend against seasonal and pandemic viral infections. Leyden Labs’ lead program is a pan-influenza nasal spray currently in clinical development (PanFlu), which has the potential to provide first-in-class influenza protection and meaningfully reduce the burden of influenza infection, including in infection from Avian Flu (H5).

Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced the publication of new findings that showcase the advantages of intranasal administration of monoclonal antibodies over systemic administration for protection against airborne viruses.

Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced it has raised $70M in funding to advance its Mucosal Protection Platform. This non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, such as influenza and coronaviruses.

Leyden Laboratories B.V., (the "Company" or "Leyden Labs"), a biotechnology company working to free people from the threat of respiratory viruses by boosting mucosal immunity, today announced the appointment of Jintanat Ananworanich, M.D., Ph.D., as chief medical officer. Dr. Ananworanich, a physician with global experience fighting infectious disease, will oversee clinical development of Leyden Labs’ portfolio of intranasal product candidates.

Leyden Laboratories B.V., (the “Company” or “Leyden Labs”) announced today the dosing of the first Phase 1 healthy volunteer cohort with a nasal spray containing PanFlu candidate CR9114. CR9114 is a universal anti-hemagglutinin stem human antibody which has been shown to provide broad protection in animal studies against influenza infection and disease.